Mary Ann Allison

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Javier Cortés, Linda T. Vahdat, Joanne L. Blum et al. · Journal of Clinical Oncology · 2010 · 215 citations

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

Stephen E. Jones, Rufus Collea, Devchand Paul et al. · The Lancet Oncology · 2013 · 134 citations

Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment

Helena R. Chang, John A. Glaspy, Mary Ann Allison et al. · Cancer · 2010 · 111 citations · Full text

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors.

Mary Ann Allison, S. Jones, Patty McGuffey · Journal of Clinical Oncology · 1989 · 79 citations

Immunology, Pathology, Pharmacotherapy +17